ERR3262564
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ESTROGEN_RESPONSE_LATE+0.400
- ADIPOGENESIS+0.300
- ALLOGRAFT_REJECTION+0.300
- BILE_ACID_METABOLISM+0.300
- ESTROGEN_RESPONSE_EARLY+0.300
- INFLAMMATORY_RESPONSE+0.300
- KRAS_SIGNALING_DN+0.300
- KRAS_SIGNALING_UP+0.300
- OXIDATIVE_PHOSPHORYLATION+0.300
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.500
- UNFOLDED_PROTEIN_RESPONSE-0.500
- DNA_REPAIR-0.400
- MITOTIC_SPINDLE-0.400
- MYC_TARGETS_V1-0.400
- E2F_TARGETS-0.300
- G2M_CHECKPOINT-0.300
- PROTEIN_SECRETION-0.300
- TGF_BETA_SIGNALING-0.200
- GLYCOLYSIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
0 twins match this tumor's tissue · 10 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1254 | Med | Medulloblastoma | 0.906 |
| 2 | BS_M4NVX721 | Ganglioglioma | — | 0.871 |
| 3 | SRR1459211 | GTEX | — | 0.870 |
| 4 | SRR1434484 | GTEX | — | 0.858 |
| 5 | SRR1444622 | GTEX | — | 0.855 |
| 6 | ERR2598280 | fetal | fetal | 0.854 |
| 7 | SRR1485333 | GTEX | — | 0.850 |
| 8 | SRR1352954 | GTEX | — | 0.846 |
| 9 | ERR2598269 | fetal | fetal | 0.846 |
| 10 | SRR656167 | GTEX | — | 0.840 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ESTROGEN_RESPONSE_LATE | 0.400 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.300 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.300 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.300 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.300 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.300 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.200 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.200 | Inavolisib | — uncovered |
| HYPOXIA | 0.200 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.200 | Inavolisib | — uncovered |